Reimbursed Care Access in Equatorial Guinea
Equatorial Guinea has no public, regulated medical framework for psychedelic-assisted therapies and enforces strict national drug control laws; most classical psychedelics (psilocybin, MDMA, DMT, mescaline, 2C-X, 5‑MeO‑DMT, ibogaine, ayahuasca) are treated as controlled/illegal with no routine medical or reimbursed access outside of authorised research. Ketamine is recognized as an essential anaesthetic agent by WHO and is used in clinical settings as an anaesthetic in low-resource health systems, but there is no publicly documented, reimbursed national program for psychedelic mental‑health indications (e.g., for depression) or for esketamine. National information on specific scheduling texts and implementation is limited in open sources; therefore most psychedelic compounds should be assumed to be criminalised outside tightly controlled medical or research contexts. [https://medlistapp.paho.org/en/list/11|WHO Model List of Essential Medicines (ketamine listing)]
Psilocybin
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.
MDMA
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.
Esketamine
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.
Ketamine
Ketamine is listed on the World Health Organization Model List of Essential Medicines as an injectable general anaesthetic and is widely recognised internationally for use in basic and emergency anaesthesia, which supports its availability for medical use in low‑resource settings. #.
In Equatorial Guinea there is evidence of functioning medical infrastructure (including recent WHO-supported improvements such as a public medical oxygen plant and regional hospital upgrades) that indicates national hospitals provide acute and surgical care where injectable anaesthetics would be used, implying ketamine is available for standard anaesthetic use in clinical settings; however, there is no publicly available national regulatory documentation or reimbursement scheme describing ketamine use for psychiatric indications (such as ketamine-assisted therapy for depression) or any national program to reimburse such off‑label mental‑health use. #.
Practical implications: ketamine is effectively available as an essential anaesthetic medicine in health facilities (used in perioperative and emergency care) but there is no documented public insurance reimbursement, national guideline, or licensed esketamine/psychedelic‑therapy program for mental‑health indications in Equatorial Guinea. Patients seeking ketamine for psychiatric indications should assume access would only be via private medical arrangements or within approved clinical research if any such trials are present.
DMT
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.
5-MeO-DMT
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.
Ibogaine
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.
Ayahuasca
Currently classified as containing controlled tryptamine(s) (such as DMT) and therefore treated as a controlled substance under national drug scheduling laws, with no authorized medical or religious exemption documented in public sources; no authorised reimbursed medical access outside approved clinical research.
Mescaline
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.
2C-X
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.